Uulke Van der Heide

Imaging technology in radiotherapy

The research in our group centers around the use of MRI for radiotherapy with an emphasis on quantitative MRI for prostate cancer.  In the phase 3 randomized FLAME trial, we investigate the potential benefit of focal boosting of the tumor in the prostate,  as visible on multi-parametric MRI.

Techniques, such as diffusion-weighted MRI, dynamic contrast MRI and T1 and T2 mapping are applied to characterize tumors and response after treatment. In collaboration with the MR-linac consortium, we investigate the potential of the Unity MR-linac for this purpose as it allows daily acquisition of quantitative MRI sequences during radiotherapy.

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.